ClinicalTrials.gg
CompletedNCT02757352COAST-XUpdated Mar 13, 2020Results posted

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis

A Phase 3 interventional study of Ixekizumab and Placebo in Axial Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 109 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-13.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.

Enrollment
13th of 31
303 · median 200
Started
2016
with 3 others
Phase 3
13 of 34
none open now
Registered
11th of 34
by date
Lead sponsor
2 of 34
Eli Lilly and Company

Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 13th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2016, is one of 13 in phase 3, and was the 11th registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Axial Spondyloarthritis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).

03

Conditions studied

  • Axial Spondyloarthritis

Keywords

  • ankylosing
  • nonradiographic spondyloarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ambulatory.
  • Diagnosis of nonradiographic axial spondyloarthritis (nr-axSpA) and fulfilling the 2009 Assessment of Spondyloarthritis International Society (ASAS) classification criteria.
  • Have a history of back pain ≥3 months with age at onset \<45 years.
  • Have active nr-axSpA defined as BASDAI ≥4 and total back pain ≥4 on a numeric rating scale (NRS) at screening and baseline.
  • Have objective signs of inflammation by presence of sacroiliitis on MRI and/or presence of elevated C-reactive protein (CRP).
  • In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.
  • If taking NSAIDS be on stable dose for at least 2 weeks prior to randomization.
  • Have a history of prior therapy for axSpA for at least 12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have radiographic sacroiliitis fulfilling the 1984 modified New York criteria.
  • Have received any prior, or are currently receiving treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents.
  • Have received a within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.
  • Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis.
  • Have a compromised immune system.
  • Have any other serious and/or uncontrolled diseases.
  • Have either a current diagnosis or a recent history of malignant disease.
  • Have had major surgery within 8 weeks of baseline, or will require surgery during the study.
  • Are pregnant or breastfeeding.
  • Have evidence of active anterior uveitis (an acute episode) within the last 42 days prior to baseline randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    Q2W Ixekizumab

    Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period. Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44.

    Drug: Ixekizumab

  • Experimental
    Q4W Ixekizumab

    Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period. Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44.

    Drug: Ixekizumab

  • Placebo comparator
    Placebo

    Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period. Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response

    ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).

    Time frame: Week 16

  2. Percentage of Participants Achieving an ASAS40 Response

    ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).

    Time frame: Week 52

Secondary outcomes

  1. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

    ASDAS is a composite index to assess disease activity in axial spondyloarthritis (axSpA). ASDAS parameters used with (C-reactive protein \[CRP\] as acute phase reactant) are: 1) Total back pain 2) Patient global 3) Peripheral pain/swelling, duration of morning stiffness 4) CRP in mg/L: ASDAScrp is calculated with the equation: 0.121 × total back pain + 0.110×patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least squares mean (LS Mean) was derived from mixed models repeated measure analysis (MMRM) with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  2. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

    ASDAS is a composite index to assess disease activity in axSpA. ASDAS parameters used (with CRP as acute phase reactant) are: 1 )Total back pain 2) Patient global 3) Peripheral pain/swelling 4) Duration of morning stiffness 5) CRP in mg/L: ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  3. Number of Participants Without Clinically Meaningful Changes in Background Therapy

    Number of participants without changes in background therapy while on originally randomized treatment.

    Time frame: Baseline through Week 52

  4. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

    The SF-36 is a 36-item patient-administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The Physical Component Summary score ranges from 0 to 100; higher scores indicate better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  5. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

    The medical outcomes study 36-item short-form health survey (SF-36) SF-36 PCS are summarized using the t-scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  6. Percentage of Participants Achieving ASDAS Low Disease Activity

    ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 16

  7. Percentage of Participants Achieving ASDAS Low Disease Activity

    ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 52

  8. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  9. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  10. Change From Baseline in Magnetic Resonance Imaging (MRI) of the Sacroiliac Joint (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score

    Both left and right SIJ are scored for bone marrow edema. Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LS Mean was derived from ANCOVA model with treatment, geographic region, screening MRI/CRP status and baseline value as fixed factors.

    Time frame: Baseline, Week 16

  11. Change From Baseline in SPARCC Enthesitis Score

    The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  12. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. Participants were asked to rate the difficulty associated with 10 individual basic functional activities. Participant responded to each question using a NRS scale (range 0 to 10), with a higher score indicating worse functioning. The participant's final BASFI score is the mean of the 10 item scores with the minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  13. Percentage of Participants Achieving ASDAS Inactive Disease

    ASDAS is a composite index to assess disease activity in axSpA. ASDAS Inactive Disease is defined as a score of less than (\<)1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 52

  14. Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

    High-sensitivity C-reactive protein (hs-CRP) was the measure of acute phase reactant and was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  15. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

    Bath Ankylosing Spondylitis Metrology Index (BASMI) is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with axSpA: 1) Lateral spinal flexion 2) Tragus-to-wall distance 3) Lumbar flexion (modified Schrober) 4) Maximal intermalleolar distance, and 5) Cervical rotation. The BASMI includes these 5 measurements that were each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  16. Change From Baseline in Chest Expansion

    While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  17. Change From Baseline in Occiput to Wall Distance

    The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  18. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

    Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed included costochondral 1 (right/left \[R/L\]), costochondral 7 (R/L), spinal iliaca anterior superior (R/L), crista iliaca (R/L), spina iliaca posterior (R/L), processus spinosus L5, and achilles tendon proximal insertion (R/L). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  19. Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC) and Swollen Joint Count (SJC) Scores of 44 Joints

    The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body). The 46 joints are assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). Swollen joint count SJC was determined by examination of 44 joints (22 joints on each side of the participants body). The joints are classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which is multiplied by 44 to obtain SJC score. Score ranges from 0 (not swollen) to 44 (all joints swollen). LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status and baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  20. Number of Participants With Anterior Uveitis

    Number of participants with anterior uveitis. Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

    Time frame: Baseline through Week 52

  21. Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

    The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  22. Change From Baseline in ASAS Health Index (ASAS HI)

    ASAS-HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS Mean was derived MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  23. Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

    Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS Mean was derived from using MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 52

  24. Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

    The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS Mean was derived from ANCOVA with treatment, geographic region, screening MRI/CRP status and baseline value.

    Time frame: Baseline, Week 52

  25. Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

    ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, the higher the score, the greater the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).

    Time frame: Baseline, Week 52

  26. Number of Participants With Treatment Emergent (TE) Anti-Ixekizumab Antibodies

    A treatment-emergent positive anti-drug antibody (TE-ADA+) participant will be defined as a 4-fold increase over a positive baseline antibody titer (Tier 3); or for a negative baseline titer, a participant with an increase from the baseline to a level of ≥ 1:10.

    Time frame: Week 52

  27. Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)

    PK trough serum concentration samples were collected at steady state (Ctrough ss)

    Time frame: Week 52

07

Results

Posted Mar 13, 2020

Participant flow

This study has 3 periods: Period 1 - Screening; Period 2 - A Double-Blind Treatment Period (Weeks 0 Up to 52); (Inadequate Responders \[IR\] Week 16-52) followed by a Follow-Up Period (Up to 24 Weeks after last visit)

Double-Blind Period (Week 0 - Week 16)
Participant flow — Double-Blind Period (Week 0 - Week 16)
MilestonePlacebo Double-Blind PeriodIxekizumab 80 mg Q4W (IxeQ4W) Double-Blind PeriodIxekizumab 80 mg Q2W (IxeQ2W) Double-Blind PeriodPBO IR/Ixe80Q2W-Open LabelIxekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open LabelIxekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open LabelPlacebo Post Treatment Follow-Up PeriodIxekizumab 80 mg Q4W Post Treatment Follow-Up PeriodIxekizumab 80 mg Q2W Post Treatment Follow-Up PeriodOther Biologic Treatment Group
Started105961020000000
Received at least one dose of study drug104961020000000
Completed9795980000000
Not completed8140000000
Withdrew: Adverse event2010000000
Withdrew: Lost to follow-up0010000000
Withdrew: Withdrawal by subject6120000000
Double-Blind Period (Week 16 - Week 52)
Participant flow — Double-Blind Period (Week 16 - Week 52)
MilestonePlacebo Double-Blind PeriodIxekizumab 80 mg Q4W (IxeQ4W) Double-Blind PeriodIxekizumab 80 mg Q2W (IxeQ2W) Double-Blind PeriodPBO IR/Ixe80Q2W-Open LabelIxekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open LabelIxekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open LabelPlacebo Post Treatment Follow-Up PeriodIxekizumab 80 mg Q4W Post Treatment Follow-Up PeriodIxekizumab 80 mg Q2W Post Treatment Follow-Up PeriodOther Biologic Treatment Group
Started9795980000000
Completed3452520000000
Not completed6343460000000
Withdrew: Adverse event0100000000
Withdrew: Lack of efficacy0100000000
Withdrew: Withdrawal by subject1140000000
Withdrew: Classified as inadequate responders (ir)6240420000000
IR-Open Label Period (Week 16 - Week 52)
Participant flow — IR-Open Label Period (Week 16 - Week 52)
MilestonePlacebo Double-Blind PeriodIxekizumab 80 mg Q4W (IxeQ4W) Double-Blind PeriodIxekizumab 80 mg Q2W (IxeQ2W) Double-Blind PeriodPBO IR/Ixe80Q2W-Open LabelIxekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open LabelIxekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open LabelPlacebo Post Treatment Follow-Up PeriodIxekizumab 80 mg Q4W Post Treatment Follow-Up PeriodIxekizumab 80 mg Q2W Post Treatment Follow-Up PeriodOther Biologic Treatment Group
Started0006240420000
Initiated other biologic rescue0002030000
Completed0005537350000
Not completed0007370000
Withdrew: Adverse event0003010000
Withdrew: Lack of efficacy0002140000
Withdrew: Pregnancy0000100000
Withdrew: Physician decision0000010000
Withdrew: Withdrawal by subject0002110000
Follow-Up Period
Participant flow — Follow-Up Period
MilestonePlacebo Double-Blind PeriodIxekizumab 80 mg Q4W (IxeQ4W) Double-Blind PeriodIxekizumab 80 mg Q2W (IxeQ2W) Double-Blind PeriodPBO IR/Ixe80Q2W-Open LabelIxekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open LabelIxekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open LabelPlacebo Post Treatment Follow-Up PeriodIxekizumab 80 mg Q4W Post Treatment Follow-Up PeriodIxekizumab 80 mg Q2W Post Treatment Follow-Up PeriodOther Biologic Treatment Group
Started00000035285
Completed00000024182
Not completed00000011103
Withdrew: Adverse event0000001020
Withdrew: Lost to follow-up0000000010
Withdrew: Lack of efficacy0000000011
Withdrew: Withdrawal by subject0000000162

Outcome measures

PrimaryPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response

ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
percentage of participantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response19.035.440.2
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Regression, Logistic · p = 0.009 · Odds ratio (or): 2.36 · 95% CI 1.23 to 4.51
  • Placebo vs Ixekizumab 80 mg Q2W · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.78 · 95% CI 1.48 to 5.25
PrimaryPercentage of Participants Achieving an ASAS40 Response

ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ASAS40 Response
percentage of participantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving an ASAS40 Response13.330.231.4
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Regression, Logistic · p = 0.004 · Odds ratio (or): 2.82 · 95% CI 1.38 to 5.77
  • Placebo vs Ixekizumab 80 mg Q2W · Regression, Logistic · p = 0.004 · Odds ratio (or): 2.85 · 95% CI 1.40 to 5.77
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

ASDAS is a composite index to assess disease activity in axial spondyloarthritis (axSpA). ASDAS parameters used with (C-reactive protein \[CRP\] as acute phase reactant) are: 1) Total back pain 2) Patient global 3) Peripheral pain/swelling, duration of morning stiffness 4) CRP in mg/L: ASDAScrp is calculated with the equation: 0.121 × total back pain + 0.110×patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least squares mean (LS Mean) was derived from mixed models repeated measure analysis (MMRM) with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-0.58 ± 0.095-1.12 ± 0.097-1.26 ± 0.095
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.54 · 95% CI -0.81 to -0.28
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.68 · 95% CI -0.94 to -0.41
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

ASDAS is a composite index to assess disease activity in axSpA. ASDAS parameters used (with CRP as acute phase reactant) are: 1 )Total back pain 2) Patient global 3) Peripheral pain/swelling 4) Duration of morning stiffness 5) CRP in mg/L: ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-0.78 ± 0.136-1.39 ± 0.116-1.47 ± 0.116
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.61 · 95% CI -0.96 to -0.26
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.69 · 95% CI -1.05 to -0.34
SecondaryNumber of Participants Without Clinically Meaningful Changes in Background Therapy

Number of participants without changes in background therapy while on originally randomized treatment.

Time frame:
Baseline through Week 52
Reported as:
Count of participants · Participants
Number of Participants Without Clinically Meaningful Changes in Background Therapy
ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Number of Participants Without Clinically Meaningful Changes in Background Therapy9890100
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

The SF-36 is a 36-item patient-administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The Physical Component Summary score ranges from 0 to 100; higher scores indicate better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score5.2103 ± 0.79998.0612 ± 0.81297.9600 ± 0.8023
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.013 · Ls mean difference: 2.8509 · 95% CI 0.6092 to 5.0926
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.015 · Ls mean difference: 2.7497 · 95% CI 0.5299 to 4.9694
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

The medical outcomes study 36-item short-form health survey (SF-36) SF-36 PCS are summarized using the t-scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score4.7210 ± 1.24598.9211 ± 1.07839.3291 ± 1.0810
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.012 · Ls mean difference: 4.2001 · 95% CI 0.9525 to 7.4477
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.006 · Ls mean difference: 4.6081 · 95% CI 1.3629 to 7.8533
SecondaryPercentage of Participants Achieving ASDAS Low Disease Activity

ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASDAS Low Disease Activity
percentage of participantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving ASDAS Low Disease Activity12.427.732.4
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Regression, Logistic · p = 0.008 · Odds ratio (or): 2.73 · 95% CI 1.30 to 5.76
  • Placebo vs Ixekizumab 80 mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.43 · 95% CI 1.66 to 7.08
SecondaryPercentage of Participants Achieving ASDAS Low Disease Activity

ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASDAS Low Disease Activity
percentage of participantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving ASDAS Low Disease Activity8.629.827.5
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.58 · 95% CI 2.02 to 10.41
  • Placebo vs Ixekizumab 80 mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.99 · 95% CI 1.76 to 9.05
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-1.51 ± 0.216-2.18 ± 0.220-2.52 ± 0.217
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.031 · Ls means square difference: -0.67 · 95% CI -1.28 to -0.06
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.001 · Ls mean difference: -1.01 · 95% CI -1.61 to -0.41
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-1.76 ± 0.305-2.89 ± 0.266-3.04 ± 0.266
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.006 · Ls mean difference: -1.13 · 95% CI -1.92 to -0.33
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.002 · Ls mean difference: -1.29 · 95% CI -2.08 to -0.49
SecondaryChange From Baseline in Magnetic Resonance Imaging (MRI) of the Sacroiliac Joint (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score

Both left and right SIJ are scored for bone marrow edema. Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LS Mean was derived from ANCOVA model with treatment, geographic region, screening MRI/CRP status and baseline value as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Sacroiliac Joint (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Sacroiliac Joint (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score-0.31 ± 0.539-3.38 ± 0.549-4.52 ± 0.530
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · ANCOVA · p = <0.001 · Ls mean difference: -3.07 · 95% CI -4.58 to -1.57
  • Placebo vs Ixekizumab 80 mg Q2W · ANCOVA · p = <0.001 · Ls mean difference: -4.20 · 95% CI -5.68 to -2.72
SecondaryChange From Baseline in SPARCC Enthesitis Score

The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in SPARCC Enthesitis Score
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in SPARCC Enthesitis Score-2.87 ± 0.447-2.99 ± 0.427-3.14 ± 0.407
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.849 · Ls mean difference: -0.12 · 95% CI -1.35 to 1.11
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.648 · Ls mean difference: -0.28 · 95% CI -1.48 to 0.93
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. Participants were asked to rate the difficulty associated with 10 individual basic functional activities. Participant responded to each question using a NRS scale (range 0 to 10), with a higher score indicating worse functioning. The participant's final BASFI score is the mean of the 10 item scores with the minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)-1.57 ± 0.333-2.63 ± 0.292-2.75 ± 0.291
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.018 · Ls mean difference: -1.06 · 95% CI -1.93 to -0.18
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.008 · Ls mean difference: -1.18 · 95% CI -2.05 to -0.31
SecondaryPercentage of Participants Achieving ASDAS Inactive Disease

ASDAS is a composite index to assess disease activity in axSpA. ASDAS Inactive Disease is defined as a score of less than (\<)1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASDAS Inactive Disease
percentage of participantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving ASDAS Inactive Disease2.913.510.8
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Regression, Logistic · p = 0.0011 · Odds ratio (or): 5.33 · 96% CI 1.47 to 19.40
  • Placebo vs Ixekizumab 80 mg Q2W · Regression, Logistic · p = 0.031 · Odds ratio (or): 4.22 · 95% CI 1.14 to 15.66
SecondaryChange From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

High-sensitivity C-reactive protein (hs-CRP) was the measure of acute phase reactant and was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligram/liter (mg/L)
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
milligram/liter (mg/L)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)-4.804 ± 2.0370-8.611 ± 2.0028-7.547 ± 1.9654
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.183 · Ls mean difference: -3.807 · 95% CI -9.418 to 1.804
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.331 · Ls mean difference: -2.743 · 95% CI -8.294 to 2.807
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

Bath Ankylosing Spondylitis Metrology Index (BASMI) is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with axSpA: 1) Lateral spinal flexion 2) Tragus-to-wall distance 3) Lumbar flexion (modified Schrober) 4) Maximal intermalleolar distance, and 5) Cervical rotation. The BASMI includes these 5 measurements that were each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)-0.17 ± 0.112-0.56 ± 0.097-0.48 ± 0.097
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.008 · Ls mean difference: -0.40 · 95% CI -0.69 to -0.10
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.038 · Ls mean difference: -0.31 · 95% CI -0.60 to -0.02
SecondaryChange From Baseline in Chest Expansion

While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Chest Expansion
centimeter (cm)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Chest Expansion0.57 ± 0.2530.62 ± 0.2060.91 ± 0.209
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.871 · Ls mean difference: 0.05 · 95% CI -0.59 to 0.70
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.295 · Ls mean difference: 0.34 · 95% CI -0.30 to 0.99
SecondaryChange From Baseline in Occiput to Wall Distance

The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · cm
Change From Baseline in Occiput to Wall Distance
cmPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Occiput to Wall Distance0.04 ± 0.312-0.42 ± 0.257-0.73 ± 0.259
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.257 · Ls mean difference: -0.46 · 95% CI -1.26 to 0.34
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.057 · Ls mean difference: -0.77 · 95% CI -1.56 to 0.02
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed included costochondral 1 (right/left \[R/L\]), costochondral 7 (R/L), spinal iliaca anterior superior (R/L), crista iliaca (R/L), spina iliaca posterior (R/L), processus spinosus L5, and achilles tendon proximal insertion (R/L). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)-2.34 ± 0.361-3.21 ± 0.342-3.19 ± 0.336
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.082 · Ls mean difference: -0.87 · 95% CI -1.85 to 0.11
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.088 · Ls mean difference: -0.85 · 95% CI -1.82 to 0.13
SecondaryChange From Baseline in Severity of Peripheral Arthritis by Tender (TJC) and Swollen Joint Count (SJC) Scores of 44 Joints

The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body). The 46 joints are assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). Swollen joint count SJC was determined by examination of 44 joints (22 joints on each side of the participants body). The joints are classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which is multiplied by 44 to obtain SJC score. Score ranges from 0 (not swollen) to 44 (all joints swollen). LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status and baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · joint counts
Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC) and Swollen Joint Count (SJC) Scores of 44 Joints
joint countsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
TJC-0.59 ± 1.039-2.38 ± 0.993-4.12 ± 0.916
SJC-3.66 ± 0.261-4.63 ± 0.237-4.41 ± 0.228
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.219 · Ls mean difference: -1.79 · 95% CI -4.66 to 1.09
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.013 · Ls mean difference: -3.53 · 95% CI -6.30 to -0.76
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.009 · Ls mean difference: -0.97 · 95% CI -1.68 to -0.26
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.034 · Ls mean difference: -0.76 · 95% CI -1.46 to -0.06
SecondaryNumber of Participants With Anterior Uveitis

Number of participants with anterior uveitis. Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

Time frame:
Baseline through Week 52
Reported as:
Count of participants · Participants
Number of Participants With Anterior Uveitis
ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Number of Participants With Anterior Uveitis212
SecondaryChange From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score-2.1 ± 0.38-2.6 ± 0.32-2.7 ± 0.32
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.325 · Ls mean difference: -0.5 · 95% CI -1.5 to 0.5
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.206 · Ls mean difference: -0.6 · 95% CI -1.6 to 0.4
SecondaryChange From Baseline in ASAS Health Index (ASAS HI)

ASAS-HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS Mean was derived MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in ASAS Health Index (ASAS HI)
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in ASAS Health Index (ASAS HI)-2.57 ± 0.455-3.16 ± 0.395-3.54 ± 0.396
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.330 · Ls mean difference: -0.59 · 95% CI -1.77 to 0.60
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.110 · Ls mean difference: -0.97 · 95% CI -2.15 to 0.22
SecondaryChange From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS Mean was derived from using MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
units on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)-2.9 ± 0.63-3.6 ± 0.52-3.6 ± 0.53
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Mixed Models Analysis · p = 0.348 · Ls mean difference: -0.8 · 95% CI -2.4 to 0.8
  • Placebo vs Ixekizumab 80 mg Q2W · Mixed Models Analysis · p = 0.386 · Ls mean difference: -0.7 · 95% CI -2.3 to 0.9
SecondaryChange From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS Mean was derived from ANCOVA with treatment, geographic region, screening MRI/CRP status and baseline value.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Overall Impairment Score-13.20 ± 3.386-26.96 ± 3.439-19.49 ± 3.221
Percentage of absenteeism-3.11 ± 2.215-9.01 ± 2.257-7.26 ± 2.151
Percentage of presenteeism-12.40 ± 3.200-26.01 ± 3.245-18.61 ± 3.047
Percentage of impairment in activities-14.42 ± 2.584-25.05 ± 2.617-24.41 ± 2.567
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · ANCOVA · p = 0.005 · Ls mean difference: -13.76 · 95% CI -23.32 to -4.20
  • Placebo vs Ixekizumab 80 mg Q2W · ANCOVA · p = 0.183 · Ls mean difference: -6.29 · 95% CI -15.58 to 3.00
  • Placebo vs Ixekizumab 80 mg Q4W · ANCOVA · p = 0.060 · Ls mean difference: -5.90 · 95% CI -12.05 to 0.26
  • Placebo vs Ixekizumab 80 mg Q2W · ANCOVA · p = 0.182 · Ls mean difference: -4.15 · 95% CI -10.27 to 1.97
  • Placebo vs Ixekizumab 80 mg Q4W · ANCOVA · p = 0.003 · Ls mean difference: -13.61 · 95% CI -22.62 to -4.60
  • Placebo vs Ixekizumab 80 mg Q2W · ANCOVA · p = 0.164 · Ls mean difference: -6.21 · 95% CI -15.00 to 2.58
  • Placebo vs Ixekizumab 80 mg Q4W · LS Mean Difference · p = 0.004 · Ls mean difference: -10.63 · 95% CI -17.85 to -3.41
  • Placebo vs Ixekizumab 80 mg Q2W · ANCOVA · p = 0.006 · Ls mean difference: -9.99 · 95% CI -17.12 to -2.86
SecondaryChange From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, the higher the score, the greater the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
score on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score-8.89 ± 29.986-7.91 ± 34.257-5.33 ± 20.935
SecondaryNumber of Participants With Treatment Emergent (TE) Anti-Ixekizumab Antibodies

A treatment-emergent positive anti-drug antibody (TE-ADA+) participant will be defined as a 4-fold increase over a positive baseline antibody titer (Tier 3); or for a negative baseline titer, a participant with an increase from the baseline to a level of ≥ 1:10.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent (TE) Anti-Ixekizumab Antibodies
ParticipantsIxe80Q2W-Q2WIxe80Q4W-Q4WPBO-Ixe80Q2WIxe80Q4W-Q2W
Number of Participants With Treatment Emergent (TE) Anti-Ixekizumab Antibodies14582
SecondaryPharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)

PK trough serum concentration samples were collected at steady state (Ctrough ss)

Time frame:
Week 52
Reported as:
Geometric mean · microgram/milliliter (μg/mL)
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)
microgram/milliliter (μg/mL)IxeQ2W (80S)/IxeQ2WIxeQ2W (80S)/IxeQ2W Open LabelIxeQ2W (160S)/IxeQ2WIxeQ2W (160s)/IxeQ2W Open LabelIxeQ4W (80S) IxeQ4WIxeQ4W (80S)/IxeQ2W Open LabelIxeQ4W(160S)/IxeQ4WIxeQ4W (160S) IxeQ2W Open LabelPBO/IxeQ2W Open Label
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)7.88 ± 739.56 ± 6010.3 ± 6110.4 ± 722.88 ± 496.45 ± 1243.54 ± 7911.5 ± 539.25 ± 66

Adverse events

Collected over Up to 76 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Double-Blind Period0/104 (0%)1/104 (1%)31/104 (29.8%)
Ixekizumab 80 mg Q4W Double-Blind Period0/96 (0%)2/96 (2.1%)43/96 (44.8%)
Ixekizumab 80 mg Q2W Double-Blind Period0/102 (0%)1/102 (1%)47/102 (46.1%)
PBO IR/IxeQ2W Open Label0/42 (0%)1/42 (2.4%)13/42 (31%)
Ixe80Q4WIR/Ixe80Q2W Open Label0/40 (0%)0/40 (0%)15/40 (37.5%)
Ixe80Q2WIR/Ixe80Q2W Open Label0/62 (0%)2/62 (3.2%)26/62 (41.9%)
Other Biologic Open Label0/5 (0%)0/5 (0%)3/5 (60%)
Placebo Post Treatment Follow-Up Period0/3 (0%)0/3 (0%)1/3 (33.3%)
Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period0/5 (0%)0/5 (0%)1/5 (20%)
Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period0/28 (0%)1/28 (3.6%)1/28 (3.6%)
Other Biologic Post Treatment Follow-Up Period0/5 (0%)0/5 (0%)0/5 (0%)
Most frequent serious events
Most frequent serious events
EventPlacebo Double-Blind PeriodIxekizumab 80 mg Q4W Double-Blind PeriodIxekizumab 80 mg Q2W Double-Blind PeriodPBO IR/IxeQ2W Open LabelIxe80Q4WIR/Ixe80Q2W Open LabelIxe80Q2WIR/Ixe80Q2W Open LabelOther Biologic Open LabelPlacebo Post Treatment Follow-Up PeriodIxekizumab 80 mg Q4W Post Treatment Follow-Up PeriodIxekizumab 80 mg Q2W Post Treatment Follow-Up PeriodOther Biologic Post Treatment Follow-Up Period
Axial spondyloarthritisMusculoskeletal and connective tissue disorders0/1040/960/1020/420/400/620/50/30/51/280/5
Focal dyscognitive seizuresNervous system disorders0/1040/960/1020/420/400/620/50/30/51/280/5
Somatic symptom disorderPsychiatric disorders0/1040/960/1021/420/400/620/50/30/50/280/5
SinusitisInfections and infestations0/1040/960/1020/420/401/620/50/30/50/280/5
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1040/960/1020/420/401/620/50/30/50/280/5
OsteoarthritisMusculoskeletal and connective tissue disorders0/1040/960/1020/420/401/620/50/30/50/280/5
Abdominal painGastrointestinal disorders0/1041/960/1020/420/400/620/50/30/50/280/5
ErysipelasInfections and infestations0/1041/960/1020/420/400/620/50/30/50/280/5
Major depressionPsychiatric disorders0/1040/961/1020/420/400/620/50/30/50/280/5
Anaphylactoid reactionImmune system disorders1/1040/960/1020/420/400/620/50/30/50/280/5
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo Double-Blind PeriodIxekizumab 80 mg Q4W Double-Blind PeriodIxekizumab 80 mg Q2W Double-Blind PeriodPBO IR/IxeQ2W Open LabelIxe80Q4WIR/Ixe80Q2W Open LabelIxe80Q2WIR/Ixe80Q2W Open LabelOther Biologic Open LabelPlacebo Post Treatment Follow-Up PeriodIxekizumab 80 mg Q4W Post Treatment Follow-Up PeriodIxekizumab 80 mg Q2W Post Treatment Follow-Up PeriodOther Biologic Post Treatment Follow-Up Period
Influenza like illnessGeneral disorders2/1040/960/1020/420/400/620/51/30/50/280/5
PharyngitisInfections and infestations4/1044/962/1022/423/403/620/51/30/50/280/5
IritisEye disorders0/1040/960/1020/420/400/620/50/31/50/280/5
NasopharyngitisInfections and infestations8/10418/9616/1022/427/406/621/50/30/50/280/5
Upper respiratory tract infectionInfections and infestations4/1044/966/1022/423/404/621/50/30/51/280/5
Back painMusculoskeletal and connective tissue disorders2/1043/962/1020/420/400/621/50/30/50/280/5
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/1041/965/1021/420/400/621/50/30/50/280/5
Injection site reactionGeneral disorders4/10411/9617/1023/423/4011/620/50/30/50/280/5
NauseaGastrointestinal disorders1/1041/961/1024/422/400/620/50/30/50/280/5
Injection site erythemaGeneral disorders1/1043/964/1022/420/405/620/50/30/50/280/5

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Mean39.9 ± 12.3640.9 ± 14.4740.0 ± 12.0140.3 ± 12.92
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Female614653160
Male445049143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Hispanic or Latino25243180
Not Hispanic or Latino685763188
Unknown or Not Reported1215835
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
American Indian or Alaska Native82313
Asian17131141
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White768083239
More than one race3159
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Argentina86923
Romania51410
United States109928
Czechia15161344
Japan65516
Russia127827
Canada1326
Austria0123
South Korea97622
Netherlands0011
Finland43310
Brazil0123
Poland19182057
Mexico14131542
Germany26311
08

Study locations

109 sites
  • Arizona Arthritis Research, PLC
    Phoenix, Arizona 85032, United States
  • TriWest Research Assocaites
    El Cajon, California 92020, United States
  • Rheumatology Center of San Diego
    Escondido, California 92025, United States
  • Care Access Research - Huntington Beach
    Huntington Beach, California 92648, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Inlande Rheumatology Clinical Trials
    Upland, California 91786, United States
  • Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
    Colorado Springs, Colorado 80920, United States
  • Clinical Research Center of CT/NY
    Danbury, Connecticut 06810, United States
  • Sarasota Arthritis Center
    Sarasota, Florida 34239, United States
  • West Broward Rheumatology Associates, Inc
    Tamarac, Florida 33321, United States
  • Marietta Rheumatology
    Marietta, Georgia 30060, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • The Arthritis & Diabetes Clinic Inc.
    Monroe, Louisiana 71203, United States
  • Osteoporosis And Clinical Trial Center
    Cumberland, Maryland 21502, United States
  • Osteoporosis And Clinical Trial Center
    Hagerstown, Maryland 21740, United States
  • Glacier View Research Institute
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Weill Cornell Physicians at Brooklyn Heights
    Brooklyn, New York 11201, United States
  • Shanahan Rheumatology & Immunotherapy
    Raleigh, North Carolina 27617, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
    Columbia, South Carolina 29204, United States
  • Seattle Rheumatology Associates, P.L.L.C.
    Seattle, Washington 98122, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Capital Federal, C1430EGF, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Ciudad Autonoma de Buenos Aire, C1428DZF, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Quilmes, B1878DVC, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Rosario, S2000CFJ, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, S2000DEJ, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    San Juan, J5402DIL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    San Miguel de Tucuman, T4000AXL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel De Tucumán, T4000BRD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Wien, 1060, Austria
  • "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
    Wien, 1090, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goiás, 74043-110, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Juiz de Fora, 36010-570, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio de Janeiro, 21941-913, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Rio de Janeiro, 22271-100, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Quebec, G1V 3M7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    St. John's, A1C 5B8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, M5T 2S8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Trois-Rivieres, G8Z 1Y2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Brno, 611 41, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Ostrava, 703 00, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pardubice, 530 02, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Praha 2, 128 50, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Uherske Hradiste, 686 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Helsinki, 00100, Finland
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Helsinki, 00290, Finland
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Hyvinkaa, 05800, Finland
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Kuopio, 70110, Finland
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Oulu, 90029, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halle (Saale), Sachsen-Anhalt 06108, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Bad Doberan, 18209, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Berlin, 10117, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20095, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Hamburg, 22081, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Herne, 44649, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Bunkyo-ku, 113-8431, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Chuo-Ku, 104-8560, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kita-gun, 761-0793, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kuwana, 511-0061, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Nankoku, 783-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nishinomiya, 663-8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Okayama, 700-8607, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 534-0021, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Osaka, 545-8586, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Sapporo, 060-8648, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Sasebo, 857-1195, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Suita-shi, 565-0871, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Tenri, 632-8552, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamagata, 990-9585, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ōsaka, 5340021, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Daejeon, 35015, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 02447, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Seoul, 03080, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Seoul, 04763, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 05030, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Seoul, 05278, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Seoul, 05505, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 06273, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44620, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44650, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Merida, 97070, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexicali, 21200, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Monterrey, 64460, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Luis Potosí, 78213, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Amsterdam, 1105 AZ, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Elblag, 82-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Lodz, 90-558, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Nadarzyn, 05-830, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Poznan, 61-397, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Swidnik, 21-040, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 03-291, Poland
  • Office: Perez-De Jesus, Amarilis
    Caguas, 00725, Puerto Rico
  • Ponce School of Medicine CAIMED Center
    Ponce, 00716, Puerto Rico
  • Mindful Medical Research
    San Juan, 00918, Puerto Rico
  • Latin Clinical Trial Center
    Santurce, 00909, Puerto Rico

Showing the first 100 of 109 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Adv Ther. 2022 Jun;39(6):2806-2819. doi: 10.1007/s12325-022-02132-2. Epub 2022 Apr 16. PubMed 35429281 ↗
  • Deodhar A, Mease P, Marzo-Ortega H, Hunter T, Sandoval D, Kronbergs A, Lauzon S, Leung A, Navarro-Compan V. Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks. BMC Rheumatol. 2021 Sep 25;5(1):50. doi: 10.1186/s41927-021-00218-y. PubMed 34560906 ↗
  • Deodhar A, Mease P, Rahman P, Navarro-Compan V, Marzo-Ortega H, Hunter T, Sandoval D, Kronbergs A, Leon L, Shan M, Leung A, De Vlam K, Strand V. Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. Rheumatol Ther. 2021 Mar;8(1):135-150. doi: 10.1007/s40744-020-00254-z. Epub 2020 Dec 7. PubMed 33284423 ↗
  • Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Leon L, Calderon DMS, Kiltz U. Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis Care Res (Hoboken). 2022 Mar;74(3):451-460. doi: 10.1002/acr.24482. Epub 2022 Jan 26. PubMed 33044756 ↗
  • Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Ostergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5. PubMed 31813637 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Mar 2019, 30 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2016
First posted
May 2, 2016
StartActual
Aug 2, 2016
Primary completionActual
Mar 1, 2019
CompletionActual
May 7, 2019
Results first posted
Mar 13, 2020
Last update
Mar 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02757352
Responsible party
Sponsor
First posted
May 2, 2016
Start date
Aug 2, 2016
Primary completion
Mar 1, 2019
Completion
May 7, 2019
Results posted
Mar 13, 2020
Last update
Mar 13, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion